Intuitive Surgical Upbeat On Q4 And 2017 Sales Results

Intuitive Surgical Inc. ISRG recently announced better-than-expected preliminary net sales results for fourth-quarter and full-year 2017. The company is scheduled to report fourth-quarter 2017 results on Jan 25, 2018. Following the announcement, the stock closed at a value of $423.76 on Jan 10.

The company expects net sales for fourth-quarter 2017 to be approximately $892 million, up 18% on a year-over-year basis. The preliminary figure is higher than the Zacks Consensus Estimate of $845.7 million.

Full-year 2017 revenues are expected to be approximately $3.1 billion, up 16% on a year-over-year basis. The company's preliminary figure compares favorably with the Zacks Consensus Estimate of $3.09 billion.

Intuitive Surgical, Inc. Price and Consensus

Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote

Preliminary fourth-quarter 2017 revenues of the instrument and accessories segment increased approximately 18% to $457 million on a year-over-year basis.

Per management, the anticipated revenue growth of the instruments and accessories segment is driven by da Vinci procedure growth.

The revenues from the da Vinci Surgical System is expected to be $$283 million, up 20% on a year-over-year basis. The company shipped 216 da Vinci Surgical Systems during the quarter.

The number of da Vinci surgeries rose approximately 17%, on a year-over-year basis in the fourth quarter. The upside can be attributed to the surge in,general surgery procedures in the United States and worldwide urologic procedures.

Service revenues increased approximately 13% to $153 million on a year-over-year basis.

Share Price Looks Up

Intuitive Surgical has had an outstanding performance on the bourses in the last year. The stock has gained 87.5%, outperforming the industry's rally of 27.2%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Intuitive Surgical, Inc. ISRG: Free Stock Analysis Report
 
Bio-Rad Laboratories, Inc. BIO: Free Stock Analysis Report
 
Magellan Health, Inc. MGLN: Free Stock Analysis Report
 
Centene Corporation CNC: Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research